Tradestie Institutional Equity Comparison Engine

NTLA vs BHVN โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

BHVN Overall Edge

BHVN Captures Institutional Edge (3โ€“0 Pillars ยท 4โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Biohaven Ltd. (BHVN) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, NTLA trades at N/M Forward P/E with -826.0% operating margin (-48.0% YoY revenue) versus BHVN at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, NTLA sits in BREAKDOWN (78th %ile IV; Dealer Gamma Walls on Pro) against BHVN sits in CONSOLIDATION (18th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
NTLA N/M vs BHVN N/M Fwd P/E
Growth & Margin Winner BHVN
Op Margin -826.0% vs 0.0% ยท YoY -48.0% vs +0.0%
Momentum & Technical Winner BHVN
1Y +12.5% vs +72.6% ยท 52W Pos 17% vs 59%
Options & Structure Winner BHVN
BREAKDOWN (78th %ile IV) vs CONSOLIDATION (18th %ile IV)
NTLA NASDAQ
Intellia Therapeutics, Inc
In Vitro & In Vivo Diagnostic Substances
$9.75
+0.52% 1D
Market Cap $1.5B
1M Return -14.62%
1Y Return +12.46%
Forward P/E N/M
Unified AI Score
50.7 / 100 HOLD
Tech 47.0 Fund 55.0 Flow 59.0 Mom 60.0
BHVN NYSE
Biohaven Ltd.
Pharmaceutical Preparations
$13.95
+0.9% 1D
Market Cap $2.1B
1M Return +29.36%
1Y Return +72.59%
Forward P/E N/M
Unified AI Score
42.1 / 100 HOLD
Tech 15.0 Fund 42.0 Flow 68.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: NTLA +12.46% BHVN +72.59% Spread: +60.13 pp (BHVN Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
NTLA TTM Op. Margin: -826.0% BHVN TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NTLA vs BHVN. Trailing 12-month operating profitability (NTLA -826.0% vs BHVN 0.0%) and valuation multiples (NTLA N/M vs BHVN N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: NTLA (3) vs BHVN (4)
Institutional Metric NTLA BHVN Criterion Row Winner
Market Capitalization Scale $1.5B $2.1B Larger Scale BHVN
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -48.0% +0.0% Higher Growth BHVN
Operating Margin (TTM) Profitability -826.0% 0.0% Higher Margin BHVN
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -62.6% -799.5% Higher ROE NTLA
52-Week Range Position Momentum 17% ($8โ€“$18) 59% ($8โ€“$18) Stronger Trend BHVN
Beta / 30D Volatility Risk Regime 2.29ฮฒ ยท 88% Vol 1.40ฮฒ ยท 111% Vol Lower Realized Risk NTLA
Unified Institutional Score Composite Signal 50.7 / 100 (HOLD) 42.1 / 100 (HOLD) Higher Composite NTLA

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full NTLA vs BHVN Buy Guide
NTLA BREAKDOWN
94d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 78th %ile
IV Regime Elevated (60thโ€“80th %ile)
Live NTLA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
BHVN CONSOLIDATION
91d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 18th %ile
IV Regime Compressed (<25th %ile)
Live BHVN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither NTLA nor BHVN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.